New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Promising biobased alternatives to controversial polar aprotic solvents There are a number of promising biobased alternatives to controversial polar aprotic solvents, as revealed in a report from Wageningen Food & Biobased Research commissioned by RIVM .
European critical loads: database, biodiversity and ecosystems at risk Approximately 79 percent of the nature reserves (Natura 2000 areas) in EU countries are estimated to be exposed to an excess of nitrogen deposition in 2020.
Dutch collaboration in One Health European Joint Programme (EJP) RIVM, Wageningen Bioveterinary Research (WBVR) and the Netherlands Centre for One Health (NCOH) are involved in a recently granted One Health European Joint Programme which will start in January 20
Meningococcal immunisation recommendations re-examined Meningococcal disease is a very serious infectious disease that can cause meningitis or blood poisoning. Children are immunised against meningococcal serogroup C at 14 months.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Livestock farming affects pulmonary function in local residents COPD patients living near livestock farms suffer more complications.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
Need for circular use of materials in construction Construction and demolition waste are being recycled on a large scale to use as a foundation for e.g. roads, but recycled building materials are hardly ever used in the construction of buildings.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.